Bin Li

ORCID: 0009-0001-7671-7118
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Esophageal and GI Pathology
  • Coronary Interventions and Diagnostics
  • Hemodynamic Monitoring and Therapy
  • Pancreatic and Hepatic Oncology Research
  • Endometrial and Cervical Cancer Treatments
  • Cardiac, Anesthesia and Surgical Outcomes
  • Cardiovascular Health and Disease Prevention
  • Head and Neck Surgical Oncology
  • Neuroendocrine Tumor Research Advances
  • Cancer Immunotherapy and Biomarkers
  • Ocular Oncology and Treatments
  • Metastasis and carcinoma case studies
  • Brain Metastases and Treatment
  • Helicobacter pylori-related gastroenterology studies
  • Liver Disease Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Lung Cancer Diagnosis and Treatment
  • Ocular Diseases and Behçet’s Syndrome
  • Endometriosis Research and Treatment
  • Gestational Trophoblastic Disease Studies
  • Knee injuries and reconstruction techniques
  • Single-cell and spatial transcriptomics
  • Cancer-related Molecular Pathways

Wuhan University
2022-2025

Zhongda Hospital Southeast University
2021-2025

Shanghai Jiao Tong University
2018-2024

Lanzhou University
2024

Lanzhou University Second Hospital
2024

Beijing Tongren Hospital
2021-2023

First Affiliated Hospital of Jiangxi Medical College
2023

Jiangxi Provincial People's Hospital
2010-2023

Capital Medical University
2021-2023

Jingdezhen University
2023

Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of camrelizumab followed by adjuvant compared alone. A total 391 patients with thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified clinical stage (I/II, III IVA) randomized in 1:1:1...

10.1038/s41591-024-03064-w article EN cc-by Nature Medicine 2024-07-02

Abstract Colorectal cancer (CRC) is a heterogeneous disease that develops through stepwise accumulation, yet the underlying mechanisms at single-cell resolution remain unclear. Here, we profiled 751,531 transcriptomes, spatial transcriptomics, and snMultiomes from 142 multistage samples, revealing cellular molecular alterations dynamic intercellular crosstalk during CRC development. Additionally, created sc-eQTL map identifying 16,833 significant pairs across 28 cell subtypes, with over 76%...

10.1158/2159-8290.cd-24-1561 article EN Cancer Discovery 2025-03-03

Postoperative recurrence remains the major cause of death after curative resection for hepatocellular carcinoma (HCC). This study was conducted to evaluate impact postoperative complications on HCC resection. The outcomes 274 patients who underwent were analysed retrospectively. Of 247 patients, 103 (37.6 %) developed complications. occurrence found be associated with a significantly higher tumor (76.2 % vs. 56.6 %, P = 0.002) and lower 5-year overall survival rate (27.7 42.1 %; 0.037) as...

10.1186/s12885-015-1720-0 article EN cc-by BMC Cancer 2015-10-14

Importance The optimal treatment for and potential benefit populations of synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC) remain unclear. Objectives To evaluate outcomes concurrent chemoradiotherapy (CCRT) to construct decision tree models predicting the risk progression mortality in patients with SOESCC. Design, Setting, Participants This prognostic study included 532 SOESCC who were treated at 2 cancer centers China from January 2012 December 2018 consisted a...

10.1001/jamanetworkopen.2022.44619 article EN cc-by-nc-nd JAMA Network Open 2022-12-01

294 Background: Perioperative treatment is very important to improve long-term survival for gastric/gastroesophageal junction cancer(GC/GEJC), The RESOLVE study showed that perioperative-SOX have a clinically meaningful improvement in patients with locally advanced GC/GEJC who had D2 gastrectomy. Adding PD-1 inhibitor the chemotherapy shown significant clinical benefits first-line of GC/GEJC. This trial was designed assess feasibility and efficacy this combination perioperative resectable...

10.1200/jco.2022.40.4_suppl.294 article EN Journal of Clinical Oncology 2022-01-19

Background: Tumors invading the depth of adventitia (T3) are most common pathological type esophageal squamous cell carcinoma (ESCC). For patients without lymph nodes metastasis, role adjuvant therapy is uncertain. This study was intended to retrospectively analyze survival effects postoperative in such patients. Methods: A total 200 with T3N0M0 (pT3N0M0) ESCC from January 2012 September 2014 were enrolled, including a surgery-alone group (Group S) 111 and surgery followed...

10.21037/jtd.2019.05.70 article EN Journal of Thoracic Disease 2019-06-01

Esophageal cancer is a common gastrointestinal and ranks sixth in tumor-related death. adenocarcinoma prevalence European countries the United States, while esophageal squamous cell carcinoma frequently observed Asian (1). Radical surgical resection combined with systematic lymph node dissection has always been used as significant approach for treating cancer.

10.21037/jtd.2018.06.75 article EN cc-by-nc-nd Journal of Thoracic Disease 2018-06-01

Objective To investigate the safety and efficacy of percutaneous coronary intervention (PCI) in patients with low left ventricular ejection fraction (LVEF) complex small artery lesions. Methods Complete or partial post-PCI revascularization was employed 16 a LVEF lesions who were unsuitable for CABG ( bypass grafting). All cases observed regards to immediate success rate operation,complication, hospitalization duration, improvement cardiac function major adverse events (including death,...

10.3760/cma.j.issn.0376-2491.2010.02.011 article EN 2010-01-12

326 Background: Patients with metastatic esophageal squamous cell carcinoma (mESCC) have dismal prognosis, immune checkpoint inhibitors (ICIs) been reported to offer objective response rate (ORR) of approximately 30% a median progression-free survival (PFS) 3.6 months for mESCC. Emerging evidence suggests that radiation might be potent immunomodulator in multiple malignancies. In this trial, we aimed assess the efficacy and safety combination camrelizumab radiotherapy chemotherapy Methods:...

10.1200/jco.2022.40.4_suppl.326 article EN Journal of Clinical Oncology 2022-01-19

Background: Elevated nocturnal heart rate (NHR) has been linked to an increased risk of cardiovascular events and mortality in hypertensive patients. However, the ability NHR predict occurrence progression target organ damage (TOD) these patients requires further investigation. This study aims evaluate predictive value forecasting presence severity TOD patients, using a combination clinical laboratory parameters. Methods: A total 145 were monitored for blood pressure rate. Patients...

10.23977/medsc.2023.040220 article EN cc-by MEDS Clinical Medicine 2023-01-01
Coming Soon ...